ASCO 2022 Conference Coverage
ASCO 2022 on CRC-403: A Phase 1/2 Study of bbT369, A Dual Targeting CAR T-Cell Drug Product With a Gene Edit, in R/R B-Cell NHL
By
ASCO 2022 Conference Coverage
FEATURING
Frederick L. Locke
By
ASCO 2022 Conference Coverage
FEATURING
Frederick L. Locke
Login to view comments.
Click here to Login
Lymphoma